Corbus pharmaceuticals holdings, inc. (CRBP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-74,875

-71,453

-62,179

-55,989

-70,211

-55,672

-49,059

-41,424

-36,651

-32,421

-29,298

-27,679

-24,571

-19,998

-14,926

-11,834

-10,207

-8,850

0

0

0

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense

12,030

11,981

10,833

9,814

8,813

7,609

7,120

6,513

5,996

5,694

5,874

5,351

4,435

3,163

1,832

1,244

1,162

1,153

0

0

0

Depreciation and amortization

906

739

621

595

564

493

403

397

306

255

221

114

101

87

0

0

0

-

-

-

-

Foreign currency exchange gain (loss), net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Loss on foreign exchange

-

-

-

-

-

70

-11

7

-13

-8

0

0

0

-

-

-

-

-

-

-

-

Operating lease right of use asset amortization

539

490

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

913

102

71

74

75

0

0

0

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Decrease in customer receivable

-

-

-

-

-

-12,500

-13,000

-12,500

-6,250

-1,000

500

0

0

1,000

0

0

0

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Decrease in prepaid expenses and other current assets

1,115

1,233

-114

-640

-1,050

-281

2,114

2,066

2,495

1,877

0

0

0

-

0

0

263

-

0

0

0

Increase in contract asset

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in other assets

-21

41

114

58

13

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase in other assets

-

-

-

-

-

-

-

-

-

40

0

0

0

-

-

-

-

-

-

-

-

(Decrease) increase in accounts payable

1,076

4,366

-586

4,373

5,162

3,904

2,251

-847

306

-885

960

1,838

2,087

1,890

2,036

689

931

972

0

0

0

Increase in accrued expenses

8,018

12,555

15,953

13,038

9,640

5,113

4,829

3,100

2,999

1,514

219

790

1,563

2,660

1,119

1,521

1,000

312

0

0

0

Increase in deferred revenue

-

-

-

-

0

-

-

-

-

-

-1,315

-762

-808

88

0

0

0

-

-

-

-

Decrease in operating lease liabilities

903

971

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by operating activities

-83,640

-45,720

-37,223

-28,983

-18,149

-30,067

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Increase in other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-17,692

-13,571

-8,973

-8,405

-5,859

-4,624

0

0

0

Purchases of property and equipment

3,132

2,742

1,700

612

1,104

2,300

2,630

2,570

1,937

707

223

247

327

353

350

284

177

114

0

0

0

Net cash used in investing activities

-3,132

-2,742

-1,700

-612

-1,104

-2,300

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-327

-353

-350

-284

-177

-114

0

0

0

Principal payments on notes payable

777

605

491

475

452

430

415

370

362

354

348

333

285

239

207

184

187

190

0

0

0

Proceeds from issuance of common stock

46,198

40,677

40,687

40,646

40,690

12,052

49,555

49,524

49,398

78,891

42,842

43,013

58,049

16,699

15,744

21,982

11,266

11,328

0

0

0

Issuance costs paid for common stock financings

2,913

2,571

2,571

2,585

2,506

690

2,941

2,949

2,922

2,940

752

726

685

63

0

0

0

-

-

-

-

Principal payments under capital lease obligation

-

0

1

2

3

4

4

4

3

3

3

3

2

3

0

0

0

-

-

-

-

Net cash provided by financing activities

43,470

38,463

38,114

38,074

38,218

11,419

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-43,301

-9,999

-809

8,478

18,964

-20,948

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

57,423

16,741

15,232

21,495

10,776

10,837

0

0

0

Net increase in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Supplemental disclosure of cash flow information and non-cash transactions:
Cash paid during the period for interest

36

29

23

13

10

10

9

12

12

12

0

0

0

-

-

-

-

-

-

-

-

Fair value of warrant issued in connection with Investment Agreement

-

-

-

-

-

6,215

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Stock issuance costs included in accounts payable or accrued expenses

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Right of use assets obtained in exchange for lease obligations

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets acquired under capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

11

0

0

0

-

-

-

-

Purchases of property and equipment included in accounts payable or accrued expenses

-

376

1,138

225

-437

1

672

614

1,087

579

20

28

-78

34

0

0

0

-

-

-

-

Write off of fully amortized leasehold improvements

-

-

-

-

-

191

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5

-

0

0

0

Unpaid stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-